ArticleThrombosis research2012
Thrombolytic efficacy of tissue plasminogen activator-loaded echogenic liposomes in a rabbit thrombus model.
Article in Thrombosis research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 73 citations in OpenAlex.
- Enhancing thrombolytic therapy in Japan-dwelling Japanese using clinical ultrasound with microbubble contrast agent.Journal of medical ultrasonics (2001) · 2026Article
- Optimized TELIP, an Echogenic Liposomal Nano-Carrier Loaded with Alteplase for Preclinical Studies.Pharmaceutics · 2026Article
- Nanoparticles for Thrombolytic Therapy in Ischemic Stroke: A Systematic Review and Meta-Analysis of Preclinical Studies.Pharmaceutics · 2025Review
- Overview of Venous Thromboembolism and Emerging Therapeutic Technologies Based on Nanocarriers-Mediated Drug Delivery Systems.Molecules (Basel, Switzerland) · 2024Review
- NanoBubble-Mediated Oxygenation: Elucidating the Underlying Molecular Mechanisms in Hypoxia and Mitochondrial-Related Pathologies.Nanomaterials (Basel, Switzerland) · 2023Review
- An Echogenic Clot Method for Thrombolysis Monitoring in Thrombotic Stroke Models.Medical research archives · 2023Article
- Targeted nano-delivery strategies for facilitating thrombolysis treatment in ischemic stroke.Drug delivery · 2021Article
- New Approaches in Nanomedicine for Ischemic Stroke.Pharmaceutics · 2021Review
- Current Strategies for Microbubble-Based Thrombus Targeting: Activation-Specific Epitopes and Small Molecular Ligands.Frontiers in bioengineering and biotechnology · 2021Review
- Ultrasound Imaging and Antithrombotic Effects of PLA-Combined FeFrontiers in medicine · 2021Article
- Potential and Applications of Nanocarriers for Efficient Delivery of Biopharmaceuticals.Pharmaceutics · 2020Review
- Investigation of chitosan-g-PEG grafted nanoparticles as a half-life enhancer carrier for tissue plasminogen activator delivery.IET nanobiotechnology · 2020Article
- Accelerating thrombolysis using a precision and clot-penetrating drug delivery strategy by nanoparticle-shelled microbubbles.Science advances · 2020Article
- Stabilizing Peri-Stent Restenosis Using a Novel Therapeutic Carrier.JACC. Basic to translational science · 2020Article
- Using Acoustic Fields to Fabricate ECM-Based Biomaterials for Regenerative Medicine Applications.Recent progress in materials · 2020Article
- Engineered microparticles and nanoparticles for fibrinolysis.Journal of thrombosis and haemostasis : JTH · 2019Review
- Targeted Delivery of Plasminogen Activators for Thrombolytic Therapy: An Integrative Evaluation.Molecules (Basel, Switzerland) · 2019Review
- Recent strategies on targeted delivery of thrombolytics.Asian journal of pharmaceutical sciences · 2019Review
- Tissue plasminogen activator-based nanothrombolysis for ischemic stroke.Expert opinion on drug delivery · 2018Article
- Thrombin-Activatable Microbubbles as Potential Ultrasound Contrast Agents for the Detection of Acute Thrombosis.ACS applied materials & interfaces · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
introductionUltrasound (US)-enhanced thrombolytic treatment protocols currently in clinical trials for stroke applications involve systemic administration of tissue plasminogen activator (tPA; Alteplase), which carries a risk of adverse bleeding events. The present study aimed to compare the thrombolytic efficacy of a tPA-loaded echogenic liposome (ELIP) formulation with insonification protocols causing rapid fragmentation or acoustically-driven diffusion. MATERIALS AND
methodsThrombi were induced in the abdominal aortas of male New Zealand white rabbits (2-3kg) using thrombin and a sclerosing agent (sodium ricinoleate) after aortic denudation with a balloon catheter. Thrombolytic and cavitation nucleation agents (200μg of tPA alone, tPA mixed with 50μg of a microbubble contrast agent, or tPA-loaded ELIP) were bolus- injected proximal to the clot through a catheter introduced into the abdominal aorta from the carotid artery. Clots were exposed to transabdominal color Doppler US (6MHz) for 30 minutes at a low mechanical index (MI=0.2) to induce sustained bubble activity (acoustically-driven diffusion), or for 2 minutes at an MI of 0.4 to cause ELIP fragmentation. Degree of recanalization was determined by Doppler flow measurements distal to the clots.
resultsAll treatments showed thrombolysis, but tPA-loaded ELIP was the most efficacious regimen. Both US treatment strategies enhanced thrombolytic activity over control conditions.
conclusionsThe thrombolytic efficacy of tPA-loaded ELIP is comparable to other clinically described effective treatment protocols, while offering the advantages of US monitoring and enhanced thrombolysis from a site-specific delivery agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.